The Duration and Determinants of Anti-SARS-CoV-2 Immunoglobulin G in Cancer Patients with SARS-CoV-2 Infection: A Longitudinal Study.
The Duration and Determinants of Anti-SARS-CoV-2 Immunoglobulin G in Cancer Patients with SARS-CoV-2 Infection: A Longitudinal Study.
复制标题
感染 SARS-CoV-2 的癌症患者中抗 SARS-CoV-2 免疫球蛋白 G 的持续时间和决定因素：一项纵向研究
DOI：
10.1007/s00284-022-02933-2
复制
发表时间：
2022-06-29
影响因子：
2.6
通讯作者：
Li, Guiling
中科院分区：
文献类型：
--
作者：
Jiang, Yao;Zhao, Yingchao;Li, Guiling
癌症患者感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的风险增加，病死率高。SARS-CoV-2感染后癌症患者抗SARS-CoV-2免疫球蛋白G（IgG）抗体的持续时间以前没有报道。我们在中国武汉的一家癌症中心进行了一项纵向研究，以确定癌症患者感染SARS-CoV-2后体液免疫应答的持续时间，并确定与抗SARS-CoV-2免疫球蛋白G（IgG）短时间（< 6个月）相关的因素。在筛查的2139名癌症患者中，78名确诊为SARS-CoV-2感染的患者被纳入本研究。39.7%的患者SARS-CoV-2 IgG抗体存在时间< 6个月。此外，接受化疗的患者更可能具有短时间的抗SARS-CoV-2 IgG（比值比5.31，95%可信区间1.09-26.02，P < 0.05）。我们的研究表明，癌症患者，特别是那些接受化疗的患者，在感染后抗SARS-CoV-2 IgG的持续时间较短，因此应优先接种疫苗。
Patients with cancer have an increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and a high case-fatality rate. The duration of anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies in cancer patients following SARS-CoV-2 infection has not been reported previously. We conducted a longitudinal study at a cancer center in Wuhan, China to determine the duration of the humoral immune response following SARS-CoV-2 infection in cancer patients and to determine factors associated with a short duration (< 6 months) of anti-SARS-CoV-2 immunoglobulin G (IgG). Of 2139 cancer patients screened, 78 with confirmed SARS-CoV-2 infection were included in this study. SARS-CoV-2 IgG antibodies were present for < 6 months in 39.7% of these patients. In addition, patients who received chemotherapy were more likely to have a short duration of anti-SARS-CoV-2 IgG (odds ratio 5.31, 95% confidence interval 1.09–26.02, P < 0.05). Our study suggests that cancer patients, especially those who were receiving chemotherapy, have a shorter anti-SARS-CoV-2 IgG duration following infection and therefore, should be prioritized for vaccination.
登录
查看更多内容
影响因子：
11.8
作者：
Wu LP;Wang NC;Chang YH;Tian XY;Na DY;Zhang LY;Zheng L;Lan T;Wang LF;Liang GD
通讯作者：
Liang GD
影响因子：
82.9
作者：
Long, Quan-Xin;Liu, Bai-Zhong;Huang, Ai-Long
通讯作者：
Huang, Ai-Long
COVID-19感染的癌症患者的临床特征：中国武汉市三家医院的回顾性病例研究
影响因子：
50.5
作者：
Zhang, L.;Zhu, F.;Zhou, M.
通讯作者：
Zhou, M.
影响因子：
56.9
作者：
Kissler, Stephen M.;Tedijanto, Christine;Lipsitch, Marc
通讯作者：
Lipsitch, Marc
影响因子：
5.8
作者：
Fotouhi F;Salehi-Vaziri M;Farahmand B;Mostafavi E;Pouriayevali MH;Jalali T;Mazaheri V;Sadat Larijani M;Tavakoli M;Eshratkhah Mohammadnejad A;Afzali N;Zokaei A;Hosseini S;Mortazavipour MM;Oskouei F;Ramezani A
通讯作者：
Ramezani A